nerves (from the level of lumbosacral nerve roots), bilateral posterior tibial, peroneal nerves, and their distal muscular branches. Multiple cutaneous and subcutaneous nodular lesions were seen at the abdominal wall, gluteal region, bilateral thigh, legs, around the celiac trunk, and along the root of mesentery encircling the mesenteric vessels. These findings were consistent with clinical diagnosis of NF. Excision biopsy of the mass was suggestive of cellular schwannoma, and that from the cutaneous nerve was suggestive of neurofibroma. At this point of time, he reported to our pain clinic and was prescribed oral tramadol 50 mg 6 hourly, paracetamol 1 g 6 hourly, gabapentin 300 mg once a day for 3 days, followed by twice a day dosing for management of pain. He was referred to oncologists for disease management. Contrast-enhanced computerized tomography of the chest, abdomen, and pelvis revealed a large, well-encapsulated, lobulated mass in the posterior compartment of the left thigh measuring 2.9 cm × 11.4 cm having areas of necrosis within. Mass extended from the upper femur diaphysis till knee joint predominantly intermuscular involving adductor muscles without joint or vascular invasion. Elongated cystic spaces are seen in the retroperitoneum encasing the inferior vena cava, aorta with its branches and mesenteric vessels. Similar lesions were noted in the bilateral presacral region. Features were suggestive of MPNST.
On follow-up at 1 week, pain relief was inadequate (NRS-6/10). Oral tramadol and gabapentin were stopped, paracetamol 1 g 6 hourly was continued, and pregabalin 75 mg twice a day was started. The patient was found to be unsuitable for surgery due to extensive lesion. Medical oncology team decided to administer ifosfamide with mesna and epirubicin-based neoadjuvant chemotherapy. Furthermore, hemostatic radiotherapy 8 Gy1# was given to control bleeding from the mass. Due to chemotherapy toxicity, it was stopped, and hip disarticulation was advised. The patient again reported to us a week later and had adequate analgesia (NRS <2/10) with prescribed medications.
dIscussIon
Loss of neurofibromin due to loss-of-function mutations in the NF-1 gene in 17q11.2 predisposes to increased tumorigenesis in these patients, and the clinical course may be complicated by the occurrence of tumors such as neurofibroma, gliomas (especially vestibular), MPNST, nonlymphocytic leukemia, and pheochromocytoma. [6, 7] These malignancies can appear at any age, and transformation to MPNST is the most common with an estimated risk of 8%-13%. [8, 9] In view of relation between MPNST and its origin predominantly from preexisting plexiform neurofibromas, patients of NF need to be assessed for its malignant transformation if any new symptoms such as "persistent pain lasting for longer than a month or pain that disturbs sleep, new or unexplained neurological deficit or sphincter disturbance, and alteration in the texture of a neurofibroma from soft to hard or rapid increase in the size of a preexisting neurofibroma" occur. [4] The mechanism of pain in such cases has not been conclusively elucidated. [10, 11] Pain induced by pressure (i.e., the Tinel's sign) is a feature of both benign and malignant tumors. Increase in local concentrations of Na v 1.8 sodium channel leading to increased axonal transmission in response to mechanical stimulation has been suggested as the cause of pressure-induced nerve pain (ectopic mechanosensitivity) in cases of nerve sheath tumors. [5] Although attempts have been made to elucidate the mechanism of pain in MPNST, no therapeutic approaches targeting them have been recommended for the management of pain in these patients. As our patient had both rest pain and pressure-induced pain, we decided to target the implicated mechanisms of pain to achieve the highest level of analgesia possible. Paracetamol was used to inhibit the formation of the pro-inflammatory compounds such as cyclooxygenase and tumor necrosis factor-alpha. [12] The neuropathic component of pain due to neuronal excitability and ectopic activity was controlled by pregabalin. [13] This case report is unique as it attempts to correlate the mechanism and target therapeutic options in the management of pain in patients of NF with MPNST.
We conclude by emphasizing that various available options for management of pain should be employed after understanding the pathophysiology behind the occurrence of pain in a clinical setting. Treatment of malignancy and management of pain should be done simultaneously.
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